CHARLOTTE, N.C., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERATM (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
Help employers find you! Check out all the jobs and post your resume.
